Css LLC 89bio, Inc. Transaction History

Css LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $7,293 - $16,905	2,415 Added 2.21%	111,693 $647,000
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $89,683 - $172,502	42,911 Added 64.66%	109,278 $352,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $125,310 - $544,466	36,322 Added 120.89%	66,367 $250,000
Q4 2021 Feb 14, 2022	BUY	$11.15 - $19.66 $23,415 - $41,286	2,100 Added 7.51%	30,045 $393,000
Q3 2021 Nov 15, 2021	BUY	$14.91 - $21.31 $74,550 - $106,550	5,000 Added 21.79%	27,945 $547,000
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $70,638 - $113,540	-4,055 Reduced 15.02%	22,945 $429,000
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $69,480 - $84,240	-3,000 Reduced 10.0%	27,000 $658,000
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $730,200 - $1.16 Million	30,000 New	30,000 $770,000

167

109M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $532M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.